Covid-19

#Cobra Biologics #Covid-19 #Scancell Holdings #Vaccines

Cobra Biologics to manufacture plasmids for Phase I clinical trial COVID-19 vaccine

Cobra Biologics is to manufacture Scancell Holdings COVID-19 vaccine. The agreement covers Good Manufacturing Practice (GMP) production of plasmid DNA needed to generate the DNA vaccine, against SARS-CoV-2, for use in a Phase I clinical trial in 2021 (COVIDITY). The project is funded by an Innovate UK grant awarded to… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Clinical trials #Covid-19

Sector professionals believe COVID-19 must trigger a change in clinical trials

As a consequence of the coronavirus pandemic, 41% of global clinical trials in fields other than COVID-19 (c.4,5001) have been delayed or put on permanent hold. Looking ahead, 74% of life science organisations say that COVID-19 will continue to compromise their ability to deliver on clinical trial objectives for the… Read More

#News

#Adeptrix #Assay development & optimisation #Avacta #Covid-19

Avacta launches BAMS assay to detect SARS-CoV-2 research test

Avacta’s BAMS assay to detect the SARS-CoV-2 virus has been launched as a research kit by its partner Adeptrix and the assay has been presented by Bruker Scientific, a mass spectrometer manufacturer, in a new application note. The bead-assisted mass spectrometry (BAMS) assay uses the Affimer reagents specific to the… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Survey finds three in ten Americans unwilling to have COVID vaccine

Almost seven in 10 Americans would be interested in receiving a COVID-19 vaccine, a study finds. But researchers say there are concerning gaps in interest, particularly among Black Americans, who suffer disproportionately from the virus. Researchers from The Ohio State University surveyed more than 2,000 Americans, asking them about their… Read More

#Covid-19 #News #Trending News

#AI / data analytics / healthtech / informatics #Biopharma #Clinical trials #Covid-19 #Drug discovery #Therapeutics

Sitting down with…Biorelate

Daniel Jamieson is the CEO and Founder of Biorelate, a biomedical curation company that aims to accelerate insight and innovation in drug discovery. Lu Rahman spoke to him about his vision for the business, how COVID-19 has affected the landscape and the technology behind his drug discovery success. Biorelate was… Read More

#Opinion

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

Social distancing shows us we’re better together

What a time to be involved in drug discovery. While COVID-19 has of course created unprecedented conditions on a global scale, it has also highlighted the extent to which this sector offers depth of knowledge, skill and innovation. It is a pleasure to learn more about the market – both… Read More

#Opinion

#Antibodies #Covid-19 #NIAID

Genetic and immunologic reasons explain severe COVID-19 cases

New findings by scientists at the National Institutes of Health and their collaborators help explain why some people with COVID-19 develop severe disease. The findings also may provide the first molecular explanation for why more men than women die from COVID-19. The researchers found that more than 10% of people… Read More

#Covid-19

#Covid-19 #UCL #Vaccines

A fifth of UK people won’t to get vaccinated against COVID-19

A fifth (22%) of people have said that when a COVID-19 vaccine is approved, they’re unlikely to get it, with 10% of people saying they were ‘very unlikely’ to get vaccinated, find UCL researchers as part of the COVID-19 Social Study. Only half (49%) of people reported being ‘very likely’… Read More

#Covid-19

#Covid-19 #Therapeutics

Exercise hormone may modulate genes linked with novel coronavirus

A study conducted by researchers at São Paulo State University (UNESP) suggests that irisin, a hormone secreted from muscles in response to exercise, could have a therapeutic effect on COVID-19 patients. When they analysed adipose cell gene expression, the researchers found that irisin modulated genes associated with replication of the… Read More

#Covid-19

#Covid-19 #Drug targets #Manchester University

Monocytes may be therapeutic target for a COVID-19 treatment

White blood cells called monocytes released into the blood from bone marrow have abnormal features in people who have COVID-19. This is according to a new study by University of Manchester immunologists at the Lydia Becker Institute. The team from the Coronavirus Immune Response and Clinical Outcome (CIRCO) consortium says… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Covid-19 #Drug candidates #Drug development #MS #Therapeutics

New for old: the value behind drug repurposing  

Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially?  More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly, drug… Read More

#Covid-19 #Exclusive Content #Trends & Analysis

#AstraZeneca #Clinical trials #Covid-19 #Drug discovery #Therapeutics #Vaccines

Where are the opportunities in global drug discovery?

With COVID-19 taking centre stage in global drug discovery, Lu Rahman looks at opportunities ahead for the sector and where attention might be focussed going forward.  It is clear from the current pandemic that opportunities arise within drug discovery and development when we don’t always expect them. COVID-19 has created… Read More

#Covid-19 #Exclusive Content #Trends & Analysis

#Covid-19 #Drug development #Drug discovery #Liverpool

Creating a world leading infection R&D hub in the UK

As the world is rocked by one of the greatest healthcare challenges in living memory, how we treat infectious diseases is becoming one of the key medical questions of our age. Hannah Randles, Health and Life Sciences Champion at Liverpool City Region’s Growth Platform explains how the region’s infectious diseases… Read More

#Covid-19 #Exclusive Content #Trends & Analysis

#Covid-19 #Daiichi Sankyo #Drug discovery #Fujifilm Toyama Chemical #Japan #Takeda

Japanese drug development: Where is the innovation? 

Lu Rahman looks at how opportunities are growing in Japanese drug development and where innovation is coming from. Japan is a fascinating drug discovery and development market. A strong pharmaceutical sector (some reports place it second globally behind the US), an ageing population and a tranche of expertise, put the… Read More

#Editor's Choice #Exclusive Content #Market Reports